Skip to main content
. Author manuscript; available in PMC: 2019 May 14.
Published in final edited form as: Expert Opin Orphan Drugs. 2018 May 14;6(5):329–343. doi: 10.1080/21678707.2018.1471983

Table 4:

Ongoing Clinical Trials of Antiplatelet Agents and Anticoagulants in Sickle Cell Disease

Drug Study Title Mechanism of Action Clinical Phase NCT Number Sponsor
Ticagrelor A Study to Assess the Effect of
Ticagrelor in Reducing the Number of
Days With Pain in Patients With Sickle
Cell Disease (Hestia2)		 Antiplatelet agent Phase 2
 NCT02482298 AstraZeneca
Rivaroxaban The Effect of Rivaroxaban in Sickle Cell
Disease		 Anticoagulant Phase 2
 NCT02072668 University of
North Carolina,
Chapel Hill
Apixaban Apixaban in Patients With Sickle Cell
Disease		 Anticoagulant Phase 3 NCT02179177 Duke University
Medical Center
Unfractionated
heparin		 Feasibility Study of Unfractionated
Heparin in Acute Chest Syndrome		 Anticoagulant;
antiadhesive agent		 Phase 2 NCT02098993 University of
Pittsburgh
Tinzaparin Therapeutic Anticoagulation Strategy for
Acute Chest Syndrome (TASC)		 Anticoagulant;
antiadhesive agent		 Phase 3 NCT02580773 Assistance
Publique–
Hopitaux de Paris